Search

Your search keyword '"Shen, Haorui"' showing total 35 results
Start Over Author "Shen, Haorui"
35 results on '"Shen, Haorui"'

8. Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial

Author

Liang, Jinhua, primary, Wang, Li, additional, Wang, Xiaodong, additional, Cui, Guohui, additional, Zhou, Jianfeng, additional, Xing, Tongyao, additional, Du, Kaixin, additional, Xu, Jingyan, additional, Wang, Luqun, additional, Liang, Rong, additional, Chen, Biyun, additional, Cheng, Jian, additional, Shen, Haorui, additional, Li, Jianyong, additional, and Xu, Wei, additional

Published
2023
Full Text
View/download PDF

21. Autologous Stem Cell Transplantation after Conditioning with Chidamide Plus Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (Chi-BEAC) for Treatment of High-Risk and Relapsed/Refractory Aggressive Lymphoma: Multi-Center, Single-Arm, Open-Label Phase II Clinical Trial

Author

Xu, Wei, primary, Xia, Yi, additional, Wang, Li, additional, Ding, Kaiyang, additional, Zhu, Huayuan, additional, Hu, Maogui, additional, Yin, Hua, additional, Wu, Jiazhu, additional, Shen, Haorui, additional, Liang, Jin-Hua, additional, and Li, Jianyong, additional

Published
2021
Full Text
View/download PDF

30. Correction: Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graftversus-host disease following allogeneic hematopoietic stem cell transplantation

Author

Zhang, Ran, primary, Wang, Xiaoxiao, additional, Hong, Mei, additional, Luo, Ting, additional, Zhao, Miaomiao, additional, Shen, Haorui, additional, Fang, Jun, additional, Li, Xiaojie, additional, Zang, Sibin, additional, Chen, Ping, additional, Nie, Dimin, additional, Zheng, Peng, additional, Wu, Qiuling, additional, and Xia, Linghui, additional

Published
2017
Full Text
View/download PDF

31. Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

Author

Zhang, Ran, primary, Wang, Xiaoxiao, additional, Hong, Mei, additional, Luo, Ting, additional, Zhao, Miaomiao, additional, Shen, Haorui, additional, Fang, Jun, additional, Li, Xiaojie, additional, Zang, Sibin, additional, Chen, Ping, additional, Nie, Dimin, additional, Zheng, Peng, additional, Wu, Qiuling, additional, and Xia, Linghui, additional

Published
2017
Full Text
View/download PDF

32. Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial.

Author

Liang J, Wang L, Wang X, Cui G, Zhou J, Xing T, Du K, Xu J, Wang L, Liang R, Chen B, Cheng J, Shen H, Li J, and Xu W

Subjects
Humans, Female, Male, Middle Aged, Adult, Aged, Benzamides therapeutic use, Benzamides administration & dosage, Young Adult, Lymphoma, T-Cell, Peripheral drug therapy, Cyclophosphamide therapeutic use, Cyclophosphamide administration & dosage, Aminopyridines therapeutic use, Aminopyridines administration & dosage, Prednisone therapeutic use, Prednisone administration & dosage, Thalidomide therapeutic use, Thalidomide administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use
Abstract

Background: Although the treatment of peripheral T-cell lymphoma (PTCL) has undergone advancements during the past several years, the response rate and long-term effects with respect to patients with PTCL remain unsatisfactory-particularly for relapsed or refractory (R/R) patients. This phase II trial was designed to explore the efficacy and safety of an all-oral regimen of chidamide plus prednisone, cyclophosphamide, and thalidomide (CPCT) for R/R PTCL patients who could not tolerate the standard chemotherapy for a variety of reasons., Methods: We conducted a multicenter phase II clinical trial in which we combined chidamide (30 mg twice weekly) with prednisone (20 mg daily after breakfast), cyclophosphamide (50 mg daily after lunch), and thalidomide (100 mg daily at bedtime) (the CPCT regimen) for a total of fewer than 12 cycles as an induction-combined treatment period, and then applied chidamide as single-drug maintenance. Forty-five patients were ultimately enrolled from August 2016 to April 2021 with respect to Chinese patients at nine centers. Our primary objective was to assess the overall response rate (ORR) after the treatment with CPCT., Results: Of the 45 enrolled patients, the optimal ORR and complete response (CR)/CR unconfirmed (CRu) were 71.1% (32/45) and 28.9% (13/45), respectively, and after a median follow-up period of 56 months, the median progression-free survival (PFS) and overall survival (OS) were 8.5 months and 17.2 months, respectively. The five-year PFS and OS rates were 21.2% (95% confidence interval [CI], 7.9-34.5%) and 43.8% (95% CI, 28.3-59.3%), respectively. The most common adverse event was neutropenia (20/45, 44.4%), but we observed no treatment-related death., Conclusion: The all-oral CPCT regimen was an effective and safe regimen for R/R PTCL patients who could not tolerate standard chemotherapy for various reasons., Trial Registration: ClinicalTrials.gov , NCT02879526., (Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.)

Published
2024
Full Text
View/download PDF

33. Spatially Selective Solvation Structure by Electronegative Micro-Arrays for Stable Lithium-Metal Anode Interface.

Author

Shen H, Yu T, Tang P, Yang H, Tan J, Bai S, and Li F

Abstract

For electrolytes with conventional lithium salt concentration, it is not easy to generate sufficient anion-derived beneficial inorganic components to stabilize the electrolyte-lithium metal anode interface due to the repulsion of the free-state anions by the anode. In this study, the above issues are solved through the strong interaction between electronegative materials and lithium ions (Li + ). A locally high Li + concentration strategy is proposed by preparing micro-arrays of electronegative nano-hydroxyapatite (nHA) on the Cu foil. It is found that the oxygen atoms in the phosphate group (-PO 4 ) of the nHA can strongly adsorb Li + to form a locally Li + -rich region, which increases the probability of anions interacting with Li + . The formation of more Li + -coordinated anions at the electrolyte-anode interface can reduce the Li + de-solvation energy barrier, and enable the anions to completely decompose into lithium fluoride (LiF) and lithium nitride (Li 3 N) on the Li metal anode. The interfacial transfer dynamics is accelerated and the Li dendrites are effectively suppressed. Under high current density, the anode exhibits a long lifespan with high Coulombic efficiency and small polarization voltage. The nHA micro-arrays achieve the targeted solvation structure at the electrolyte-anode interface while ensuring conventional lithium salt concentration in the bulk electrolyte., (© 2023 Wiley-VCH GmbH.)

Published
2024
Full Text
View/download PDF

34. Role of endothelial-microparticles and the tissue factor pathway in ginsenoside Rb1-mediated prevention of umbilical vein endothelial cell injury.

Author

Zhao M, Xie J, Shen H, Wang X, Wu Q, and Xia L

Abstract

Hepatic veno-occlusive disease (VOD) is a life-threatening complication of hematopoietic stem cell transplantation, which urgently requires effective prevention and treatment. Endothelial damage is recognized as the first event in patients with hepatic VOD. However, the mechanism by which endothelial injury induces thrombosis in hepatic VOD is still not clear. In the present study, monocrotaline (MCT) was used to induce endothelial cell injury in EA.hy926 cells to imitate in vitro hepatic VOD. MCT significantly increased apoptosis in EA.hy926 endothelial cells and the secretion of endothelial microparticles (EMPs) which can be used to reflect the level of endothelial injury. Additionally, MCT significantly enhanced the expression of soluble tissue factor (TF) and EMP-bound TF protein, suggesting that EMPs may participate in the development of hepatic VOD by regulating coagulation. Ginsenoside Rb1, a major constituent and effective ingredient of Panax ginseng, was found to significantly decrease MCT-induced endothelial injury and release of EMPs. Moreover, Ginsenoside Rb1 decreased soluble TF released by EA.hy926 cells and EMP-bound TF protein induced by MCT. These data suggest that ginsenoside Rb1 may serve as a potent prophylactic and/or as a treatment of hepatic VOD by protecting endothelial cells and preventing microthrombosis induced by endothelial injury., (Copyright: © Zhao et al.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results